MacroGenics to Participate in Guggenheim Healthcare Talks Idea Forum
ROCKVILLE, MD, Feb. 13, 2019 (GLOBE NEWSWIRE) --
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the Guggenheim Healthcare Talks Idea Forum - Oncology Day. Scott Koenig, M.D., Ph.D., President and Chief Executive Officer of MacroGenics, will participate in a fireside chat at the conference in New York City on February 14, 2019, at 10:30 a.m. ET.
A webcast of the presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days after the conference.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
Jim Karrels, Senior Vice President, CFO
1-301-251-5172, firstname.lastname@example.orgKaren Sharma, Senior Vice President
MacDougall Biomedical Communications
Source: MacroGenics, Inc.